Work

First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-696

Authors: Heather Landau, Shahzad Raza, Aaron Rosenberg, Jeffrey Zonder, Raymond Comenzo, Vaishali Sanchorawala, Michaela Liedtke, Amandeep Godara, Michael Rosenzweig, Charlotte Hughes, Eugene Brailovski, Mehrdad Abedi, Sham Mailankody, Jae Park, David Marks, Sridevi Rajeeve, Jennifer Liu

Institutions: Memorial Sloan Kettering Cancer Center, Cleveland Clinic, UC Davis Comprehensive Cancer Center, University of California, Davis, The Barbara Ann Karmanos Cancer Institute, Tufts Medical Center, Boston University, Boston Medical Center, Stanford Medicine, Stanford University, University of Utah, Huntsman Cancer Institute, City Of Hope National Medical Center

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417017872

Cites:

Cited by: 3

Related to: